Tislelizumab belongs to a class of drugs called immune checkpoint inhibitors. These drugs work by helping to activate the body’s own immune defences in order to target and destroy cancer cells.
Tislelizumab targets the immune checkpoint molecule PD-1. This is similar to Nivolumab (Opdivo®), which is a Health Canada-approved immunotherapy for kidney cancer.
KFA115 is an experimental cancer therapy developed by Novartis Pharmaceuticals.
Since this drug is still in the clinical trial phase, it has the placeholder name KFA115 rather than a commercial trade name.
This is a phase 1 study that will investigate the safety and effectiveness of KFA115 either alone or in combination with Tislelizumab in patients with several different cancer types, including kidney cancer.
The treatment you receive will be assigned at random by the doctor overseeing your care.
Group 1: KFA115 alone
Group 2: KFA115 followed by Tislelizumab
Group 3: KFA115 + Tislelizumab concurrently
There is no control group in the study, so there will be no “placebo”, and all eligible patients will receive treatment.
- Clear Cell Kidney Cancer Only
- Advanced kidney cancer that cannot be removed by surgery
- Patients must have completed at least one line of prior anti-PD(L)1 immunotherapy (e.g. Pembrolizumab or Nivolumab)
Additional eligibility criteria will apply. Please speak to your doctor.
Find out more about this study.
|Hospital / Cancer Centre||Principal Investigator||Location||Trial Status|
|Hospital / Cancer CentrePrincess Margaret Cancer Centre||Principal InvestigatorNot Given||LocationToronto, ON||Trial StatusRecruiting|